Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trialAndrea Sartore‐Bianchi, Salvatore Siena, Giulia Siravegna et al.|The Lancet Oncology|2016Cited by 1k
DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant TherapyFrank A. Sinicrope, Daniel J. Sargent, Nathan R. Foster et al.|JNCI Journal of the National Cancer Institute|2011Cited by 527
The genomic landscape of response to EGFR blockade in colorectal cancerAndrea Bertotti, Victor E. Velculescu, Eniko Papp et al.|Nature|2015Cited by 495
Assessment of a HER2 scoring system for colorectal cancer: results from a validation studyEmanuele Valtorta, Marcello Gambacorta, Cosimo Martino et al.|Modern Pathology|2015Cited by 317
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trialAndrea Sartore‐Bianchi, Alberto Bardelli, Filippo Pietrantonio et al.|Nature Medicine|2022Cited by 259